Drug Overview

Tivozanib hydrochloride is a potent, Drug selective vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor designed as a targeted therapy for advanced renal cell carcinoma, minimizing off-target effects through its high specificity and long half-life. Key attributes include:

Generic name: Tivozanib hydrochloride
US Brand names: Fotivda
Drug Class: Tyrosine kinase inhibitor (targeted therapy against VEGFRs), highlighted as a “Smart Drug” and “Targeted Therapy” for its precise inhibition of angiogenesis pathways
Route of Administration: Oral capsules
FDA Approval Status: Approved March 10, 2021, for relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies; additional approvals in Europe as Fotivda since 2017

What Is It and How Does It Work? (Mechanism of Action)

Tivozanib hydrochloride acts as a quinoline urea derivative that potently and selectively inhibits VEGFR signaling at the molecular level, disrupting tumor angiogenesis by blocking endothelial cell proliferation and vascular permeability essential for cancer growth. Its detailed mechanisms include:

Binds with high affinity (IC50 in low nanomolar range) to VEGFR-1, VEGFR-2, and VEGFR-3 intracellular tyrosine kinase domains, preventing autophosphorylation and activation upon VEGF ligand binding
Inhibits downstream signaling cascades, including PLCγ-PKC, MAPK/ERK (proliferation and survival), PI3K/AKT (cell migration and anti-apoptosis), and STAT pathways in endothelial cells, halting VEGF-induced biochemical responses
Suppresses tumor vascularization by reducing endothelial cell migration, proliferation, and tube formation; minimal inhibition of off-target kinases like c-KIT and PDGFRβ at therapeutic doses due to >10-fold higher IC50
Reduces hypoxia-inducible factor (HIF)-driven VEGF overexpression in RCC cells with VHL mutations, breaking the angiogenic feedback loop without broad cytotoxicity

FDA Approved Clinical Indications

As a targeted therapy, tivozanib focuses exclusively on oncological applications in vascular-dependent tumors like RCC, with no approvals outside malignancy contexts. Indications comprise:

Relapsed or refractory advanced renal cell carcinoma in adults following two or more prior systemic therapies
Oncological uses (if any): Advanced RCC (relapsed/refractory post prior lines, including anti-angiogenic agents)
Non-oncological uses (if any): None

Dosage and Administration Protocols

Tivozanib dosing follows a 21-day on/7-day off cycle to balance efficacy and toxicity management, taken orally without regard to food; no infusion required, but dose reductions for toxicities and specific hepatic adjustments apply. Protocols are outlined below:

Indication	Dose	Frequency	Administration Notes	Dose Adjustments
Relapsed/Refractory Advanced RCC (Adults)	1.34 mg (equivalent to 1.6 mg tivozanib free base) once daily	Days 1-21 of 28-day cycle (21 days on, 7 days off)	Oral capsules; swallow whole; may take with or without food	Reduce to 0.89 mg (1.0 mg free base) for intolerable Grade 2 or any Grade 3/4 non-hematologic toxicity; further to 0.67 mg (0.8 mg free base); permanently discontinue if intolerable at lowest dose. Hepatic: Mild (Child-Pugh A) no change; Moderate (B) start 0.89 mg, max 1.34 mg; Severe (C) avoid. No renal adjustment needed (mild-moderate CrCL ≥30 mL/min); avoid if CrCL <30 mL/min

Clinical Efficacy and Research Results

Clinical trials from 2020-2025, including the pivotal TIVO-3 study, demonstrate tivozanib’s efficacy in late-line RCC with prolonged progression-free survival (PFS) compared to sorafenib, alongside exploratory combination data. Key numerical outcomes include:

TIVO-3 phase 3 trial (2020, n=355): Median PFS 5.6 months vs. 3.6 months sorafenib (HR 0.73, 95% CI 0.56-0.95, p=0.016); objective response rate (ORR) 16.4% vs. 11.1%; supported FDA approval
Overall survival (OS) in TIVO-3: 16.4 months vs. 14.9 months (HR 0.97, not significant but favorable trend); disease control rate 59% at 6 months
Post-2021 real-world data (2020-2025): PFS 7.3-11.9 months in third-line; 2024 subgroup analyses show 8.3 months PFS in prior immunotherapy patients
Ongoing trials (e.g., TiTE-C18, 2023-2025): Combinations with pembrolizumab yield ORR 35-45%, median PFS 11-15 months in first-line metastatic RCC

Safety Profile and Side Effects

No Black Box Warning applies to tivozanib, though vigilant monitoring for hypertension and hepatotoxicity remains essential due to VEGFR inhibition class effects.

Common Side Effects (>10%)

Frequently observed due to anti-angiogenic mechanisms, these are mostly manageable with supportive care:

Hypertension (all grades 39%, Grade ≥3 22%), diarrhea (22%), fatigue (20%), dysphonia/hoarseness (19%), nausea (16%), palmar-plantar erythrodysesthesia (14%), decreased appetite (13%), cough (12%)
Management: Antihypertensives (e.g., ACE inhibitors) for BP >140/90 mmHg; dose reduce for persistent Grade 2; antidiarrheals and hydration; topical emollients for hand-foot syndrome

Serious Adverse Events

Less common but require dose interruption or discontinuation (14% in trials):

Severe hypertension (Grade ≥3 25%), arterial/venous thromboembolism (5-7%), hepatotoxicity (ALT/AST >3x ULN 8%, >5x ULN 2%), hemorrhage (3%), posterior reversible encephalopathy syndrome (PRES, rare)
Management: Interrupt for Grade 3/4 non-hematologic events until recovery to ≤Grade 1; permanently discontinue for life-threatening events, confirmed hepatotoxicity, or recurrent Grade 4 hypertension; monitor BP weekly initially, LFTs monthly

Connection to Stem Cell and Regenerative Medicine (If Applicable)

No dedicated research links tivozanib to stem cell therapies or regenerative medicine; skip heading as per guidelines.

Patient Management and Practical Recommendations

Proactive monitoring optimizes tivozanib outcomes in RCC patients, emphasizing cardiovascular and hepatic surveillance alongside adherence to cycle timing. Essential guidance includes:

Pre-treatment tests: Blood pressure assessment, liver function tests (ALT/AST ≤2.5x ULN), renal function (CrCL ≥30 mL/min), ECG (QTc <470 ms), CBC, urinalysis for proteinuria
Precautions during treatment: Monitor BP daily first month then weekly; avoid in uncontrolled hypertension (>160/100 mmHg); use contraception (effective non-hormonal) during and 1 month after (teratogenic risk); CYP3A4 interactions (avoid strong inducers/inhibitors)
Do’s and Don’ts:
- Do check BP daily and log readings; report >140/90 mmHg promptly
- Do maintain hydration and use moisturizers for skin toxicities
- Do inform provider of new chest pain, headaches, or vision changes (thromboembolic/PRES risks)
- Don’t take with grapefruit juice or strong CYP3A4 modulators without adjustment
- Don’t drive if severe fatigue or hypertension occurs
- Don’t exceed prescribed cycle; permanent discontinue after two dose reductions

Legal Disclaimer

This guide provides general educational information about tivozanib hydrochloride and does not constitute medical advice, diagnosis, or treatment recommendations. Treatment decisions should involve consultation with qualified healthcare professionals, considering individual health status, and reference the latest FDA-approved prescribing information.